Discounted Cash Flow Rating

Sell

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Neutral

Analyst Rating

Sell

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Strong Buy

Standard Deviation

Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Seres Therapeutics, Inc. (MCRB)

Pharmaceutical Preparations

https://www.serestherapeutics.com

Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.

200 SIDNEY STREET
CAMBRIDGE, MA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/26/2015

Market Cap

135,799,245

Shares Outstanding

129,259,999

Weighted SO

129,257,199

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

SYRS --.--%

IOVA --.--%

VCYT --.--%

NSTG --.--%

FATE --.--%

Beta

1.9570

Last Div

0.0000

Range

0.54-3.67

Chg

0.0100

Avg Vol

4052822

Mkt Cap

135799245

Exch

NASDAQ

Country

US

Phone

617 945 9626

DCF Diff

1.0287

DCF

-0.0187

Div Yield

0.0000

P/S

363.0996

EV Multiple

-1.8245

P/FV

-1.5574

Div Yield %

0.0000

P/E

-0.8365

PEG

-0.0331

Payout

0.0000

Current Ratio

1.3785

Quick Ratio

0.8890

Cash Ratio

0.6578

DSO

18153.3824

DIO

2561.7673

Op Cycle

20715.1497

DPO

232.4573

CCC

20482.6924

Gross Margin

-19.1898

Op Margin

-434.5749

Pretax Margin

-433.4358

Net Margin

-433.4358

Eff Tax Rate

-0.0047

ROA

-0.5039

ROE

3.1356

ROCE

-0.7615

NI/EBT

1.0000

EBT/EBIT

0.9974

EBIT/Rev

-434.5749

Debt Ratio

0.3472

D/E

-1.2827

LT Debt/Cap

6.6468

Total Debt/Cap

4.5374

Int Coverage

-17.5576

CF/Debt

-1.6277

Equity Multi

-3.6949

Rec Turnover

0.0201

Pay Turnover

1.5702

Inv Turnover

0.1425

FA Turnover

0.0031

Asset Turnover

0.0012

OCF/Share

-1.1999

FCF/Share

-1.2186

Cash/Share

0.4701

OCF/Sales

-486.0989

FCF/OCF

1.0156

CF Coverage

-1.6277

ST Coverage

-19.7717

CapEx Coverage

-64.1273

Div&CapEx Cov

-64.1273

P/BV

-1.5574

P/B

-1.5574

P/S

363.0996

P/E

-0.8365

P/FCF

-0.7355

P/OCF

-0.7459

P/CF

-0.7459

PEG

-0.0331

P/S

363.0996

EV Multiple

-1.8245

P/FV

-1.5574

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 22, 04:30 Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight

Revenue Product Segmentation